CDC25B is overexpressed in ovarian cancer and is associated with poor patient prognosis; the CDC25B inhibitor WG-391D can significantly inhibit the malignant proliferation of ovarian cancer cells and the growth of transplanted tumors [39]. Here, CDC25B is linked to ovarian carcinoma.